August 1, 2025
In the rapidly evolving world of biotechnology, where innovation meets investment, understanding the intricacies of biotech stocks and market trends is crucial for stakeholders in economic development, academia, government, and the life sciences sector. The latest episode of the Favorable Environments Podcast, features a conversation with Wassim Laroussi, founder of the YouTube channel The Biotech Investor. Laroussi shares his unconventional journey into biotech and offers practical insights for evaluating public biotech companies.
From Pharmacy Technician to Biotech Investor: Laroussi’s Unconventional Path
Wassim Laroussi’s entry into biotech wasn’t a straight line but a series of pivots driven by curiosity and practicality. Growing up with dreams of becoming a professional soccer player, Laroussi turned to Google at age 22 to search for the “best-paid jobs in the US.”. Pharmacy emerged as a viable option, sparking his interest in how chemistry impacts human health. He began as a pharmacy technician at CVS, where long hours and repetitive tasks taught him the basics of drug recognition and compounding. However, realizing the limited creative input in the role, he transitioned to software development at a pharmacy benefits management firm, fixing bugs in claims processing systems.
Laroussi’s breakthrough came during his time at IQVIA, managing quality systems for major pharmaceutical clients. During the COVID-19 pandemic, the surge in public interest in clinical trials inspired him to dig deeper into this technical topic. Blending this with his longstanding fascination for finance, Laroussi launched The Biotech Investor YouTube in 2024. Today, with videos garnering thousands of views—such as his analysis of Madrigal Pharmaceuticals, which has nearly 20,000 views— Laroussi educates viewers on breaking down biotech stocks without relying solely on charts. He accomplishes all of this by creating incredibly engaging videos with animations and by translating the technical science into an easy-to-understand way.
Key Trends and Strategies in Biotech Investing
Laroussi demystifies biotech investing for beginners, emphasizing that it’s not about volatile charts but understanding the underlying business. Biotech companies, often startups with no revenue for 7-10 years post-IPO, rely on funding to advance molecules through clinical trials to FDA approval. “If you’re new, don’t look at charts,” Laroussi advises. “Imagine yourself as a billionaire buying the entire company—would it be worth it?”
He highlights current trends, including a shift away from “zombie companies” funded during low-interest COVID eras toward more scrutinized investments. With interest rates influencing funding—biotech is highly sensitive to rate changes— Laroussi predicts increased mergers and acquisitions in oncology and obesity sectors. Data from PitchBook supports this: biotech M&A deals in Q4 2024 totaled $32.1 billion, up 20% from the previous year, driven by successes in these areas.
For life science professionals, Laroussi stresses the binary nature of biotech: a failed molecule can send a company’s value to zero, unlike consumer tech where iterations are possible. Drawing from investor Peter Lynch, he urges thorough research, akin to buying a household appliance. In his Madrigal analysis, Laroussi evaluated insider trades, hiring patterns, and FDA breakthrough designations, predicting potential market impact for their fatty liver drug, which could serve millions in the US alone.
The Future of Biotech: Global Impact and Collaborative Opportunities
Looking ahead, Laroussi envisions biotech as a tool for “soft power,” extending beyond US borders to improve global health. With the US population near 340 million, drugs developed here benefit humanity worldwide, fostering international collaboration as seen during COVID vaccine efforts.
The content in this episode is not financial or legal advice. Please consult a qualified professional for investment guidance.
To stay connected with USD Discovery District, please follow us on LinkedIn.
We are leasing now! Please visit usddiscovery.com/lease for more information.
This episode is made possible by South Dakota First Captial. Learn more at southdakotafirst.com.
About this Guest
Wassim Laroussi is the founder and creator of The Biotech Investor Youtube channel.
The Biotech Investor is dedicated to exploring the biotechnology sector, with a focus on small to medium-sized companies developing innovative therapies and medications. The channel provides biweekly financial analyses of promising biotech stocks, offering insights into their potential impact on healthcare. Each episode covers recent developments and key factors for investors to consider. Aimed at both experienced and new investors, The Biotech Investor delivers clear, detailed information to support informed decision-making in the evolving world of biotechnology.
Dr. Vincent Keereman is the Chief Medical Officer and co-founder of Xeos, a medtech company with the goal to eliminate the risk of resurgery through smarter specimen imaging.
This episode features a conversation with Jason Foster. Jason is a dynamic leader with over 20 years of experience in the healthcare and technology sectors across the US, UK, and Europe. As the Chief Executive Officer of Ori Biotech, he spearheads the company’s efforts in revolutionizing cell and gene therapy manufacturing technology.
Max G. Ostermeier (MBA) is the co-founder and General Manager of Implandata Ophthalmic Products GmbH. He brings extensive experience in the commercial development of advanced technologies, building operational capabilities for rapidly growing companies, and creating businesses that attract global acquirers.
As a serial entrepreneur, Max founded and managed Odicrain GmbH, a German medical device start-up that developed a pioneering portable device for the rapid detection of intracranial bleedings, which was acquired by a US-based company in 2007. He also co-founded and served as CEO of Cranium Telemetrics GmbH, a medical technology company specializing in innovative neurosurgical products, which was acquired by a leading US medical device company four years after its founding. Additionally, Max played a key role in establishing a biotech entity for a globally leading fine chemistry company, where he served as General Manager and Vice-President until its acquisition by Sigma Aldrich.
By submitting your email to subscribe, you agree to our Privacy Policy.
